loader image
Thursday, December 18, 2025
87.4 F
McAllen
- Advertisement -

Genetic Score Detects Those at Risk for Sudden Cardiac Death

Translate to Spanish or other 102 languages!

The study, published today in the Journal of the American College of Cardiology, shows that patients with coronary artery disease without severely impaired heart function had the highest polygenic risk score, translating to a 77% increased risk for sudden cardiac death. Image for illustration purposes
The study, published today in the Journal of the American College of Cardiology, shows that patients with coronary artery disease without severely impaired heart function had the highest polygenic risk score, translating to a 77% increased risk for sudden cardiac death. Image for illustration purposes

Mega Doctor News

- Advertisement -

By Cedars-Sinai

Newswise — LOS ANGELES – Researchers in the Smidt Heart Institute at Cedars-Sinai are one step closer to identifying patients at highest risk for developing sudden cardiac death—an electrical malfunction in the heart that causes it to stop beating.

To identify those at highest risk, researchers used a polygenic risk score that has been previously shown successful in predicting coronary artery disease. This Cedars-Sinai study, however, is the first study proven to be effective at identifying coronary artery disease patients at highest risk for sudden cardiac death.

- Advertisement -

The study, published today in the Journal of the American College of Cardiology, shows that patients with coronary artery disease without severely impaired heart function had the highest polygenic risk score, translating to a 77% increased risk for sudden cardiac death.

“In order to better predict and prevent sudden cardiac death, we must first understand the genetic connection between it and coronary artery disease,” said Roopinder Sandhu, MD, MPH,  associate professor of Cardiology, and first author of the study. “We found incorporating information from this genetic risk score improved our ability to predict sudden death beyond the contributions of other known risk markers. Most exciting, the genetics were able to identify patients where sudden death was more likely to limit their life expectancy.”

Unlike heart attacks (myocardial infarctions), which are typically caused by clogged coronary arteries reducing blood flow to the heart muscle, sudden cardiac death most often results from the sudden onset of erratic electrical activity that impairs the pumping function of the heart. Patients may have little or no warning, and the disorder usually causes death within minutes if no resuscitation is performed.

Sudden cardiac death—also called sudden cardiac arrest—accounts for approximately 300,000 deaths each year in the U.S. and is a leading international health problem, responsible for 15% to 20% of all deaths. Coronary artery disease is the most common underlying reason for sudden cardiac death. Sandhu says in the future, this work may help better identify patients who would benefit most from lifesaving therapies like a defibrillator.

- Advertisement -

At present, most sudden cardiac deaths—70%—occur in patients who do not meet current guidelines for prevention with defibrillator therapy. Thus, contemporary practice not only neglects most individuals who develop sudden cardiac deathbut also involves electrophysiologists placing defibrillators in patients with advanced heart disease who are often unlikely to benefit due to limited life expectancy.

The JACC study is based on data from the National Institutes of Health-sponsored PRE-DETERMINE observational study, which has aimed to more accurately identify people at risk for sudden cardiac death among the larger pool of coronary artery disease patients who do not have advanced heart disease.

Christine Albert, MD, MPH, chair of the Department of Cardiology in the Smidt Heart Institute and senior author, said, “This study indicates there is opportunity to identify patients at highest risk for sudden cardiac death, and then offering meaningful, preventative treatment solutions like a defibrillator. Based on our pivotal research, we now have the foundation to achieve this.” 

Funding: PREDETERMINE was supported by research grants from the National Heart, Lung, and Blood Institute R01HL091069, St. Jude Medical Inc., and St. Jude Medical Foundation (to CMA). Genetic analysis was supported by grants 1K08HG010155 and 1U01HG011719 (to A.V.K.) from the National Human Genome Research Institute.

Read more from the Cedars-Sinai Blog: Women’s Hearts at Risk

SEE ORIGINAL STUDY

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Uniting Experts to Revolutionize Cancer Treatment

More than 70% of all cancers are impacted by mutations caused by a group of DNA-editing enzymes that drives tumor growth and drug resistance. The apolipoprotein B mRNA-editing enzyme catalytic polypeptide, or APOBEC, family, is a dominant factor in many cancers including bladder, breast, cervical, head and neck and lung.

Early Findings Show Breast Cancer Vaccine Produces Immune Response

Cleveland Clinic released its findings from the first phase of the clinical trial for the preventive breast cancer vaccine. 

Blood Analysis Shows Whether Brain Cancer Treatment is Working

Mega Doctor News By University of Michigan Newswise — The effectiveness of chemotherapy for brain...

The Microbial Pathway That Shuts Down Diabetes Inflammation

Globally, diabetes affects roughly 529 million individuals. In the United States, estimates suggest that more than 30 million people are living with type 2 diabetes.
- Advertisement -
×